The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to ...

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

Panelists discuss how the new nilotinib formulation offers improved convenience by eliminating fasting requirements which may enhance adherence, while emphasizing that clinicians should remain ...

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib ...

A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.